Please login to the form below

Not currently logged in

The Research Partnership makes senior US appointments

Paul Dick joins from IMS Health and Phil Rosenberg arrives from BioVid

The Research Partnership Paul DickThe Research Partnership has bolstered its US team with the appointments of Paul Dick as vice president of business development and Phil Rosenberg as research director.

Dick (pictured right) joins the London-headquartered company from IMS Health, where he ran the global market measurement group for nine years as senior director of US sales.

Prior to that he served at Wyeth for four years as international market research manager.

Meanwhile, Rosenberg arrives at The Research Partnership from US-based research firm BioVid Corporation.

He has over 25 years' experience has previously held senior market research positions at companies such as GfK and @Futures.

The Research Partnership has also appointed Sarah Tax to its US office as a research executive from custom qualitative healthcare agency Karchner Marketing Research.

US president Harriet Kozak said: “We are delighted to welcome these talented individuals to the US team, particularly Paul and Phil who we have known for many years.

“We have been looking to expand our US operations and these appointments mean that we now have a team of 15 researchers based in our Philadelphia office. With these talented individuals on board, we look forward to consolidating our US business and making new client acquisitions in both global and domestic research.”

12th September 2012

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...